NEWRON PHARMACEUT. EO-20 Cash Flow-to-Debt Ratio
NEWRON PHARMACEUT. EO-20 cash flow-to-debt ratio. NEWRON PHARMACEUT. EO-20 (NP5) has a Cash Flow-to-Debt Ratio of 0.63x as of December 2025, meaning its operating cash flow of €32.35 Million could theoretically repay 1% of its total liabilities (€51.19 Million) in one year. Check earnings quality score of NEWRON PHARMACEUT. EO-20 to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of NEWRON PHARMACEUT. EO-20 (2021–2025)
Cash flow-to-debt ratio of NEWRON PHARMACEUT. EO-20 from 2021 to 2025. Historical debt coverage capacity for NEWRON PHARMACEUT. EO-20 across 5 annual periods. Check total reinvestment intensity of NEWRON PHARMACEUT. EO-20 to assess the company's total reinvestment commitment from operating cash flow.
NEWRON PHARMACEUT. EO-20 Cash Flow-to-Debt Ratio by Year (2021–2025)
NEWRON PHARMACEUT. EO-20 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for NEWRON PHARMACEUT. EO-20. For the full cash flow conversion analysis, see NEWRON PHARMACEUT. EO-20 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.63x | €32.35 Million | €51.19 Million | ▲ +324.1% |
| 2024 | -0.28x | €-17.61 Million | €62.45 Million | ▼ -55.1% |
| 2023 | -0.18x | €-10.14 Million | €55.77 Million | ▲ +16.0% |
| 2022 | -0.22x | €-11.09 Million | €51.23 Million | ▲ +10.4% |
| 2021 | -0.24x | €-11.45 Million | €47.38 Million | — |